{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:12Z","timestamp":1761895692108},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T00:00:00Z","timestamp":1373500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the pattern of use of anticholinergic drugs for overactive bladder among women in Norway with regard to persistence, adherence and switch rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting and sample<\/jats:title><jats:p>Data from the Norwegian Prescription Database on prescriptions for tolterodine, solifenacin, darifenacin and fesoterodine filled in Norwegian pharmacies from 1 January 2004 to 31 December 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and main outcome measures<\/jats:title><jats:p>Data from the database were analysed at an individual level, and drug persistence, discontinuation rates and switch rates during a follow\u2010up period of 365\u00a0days after the first prescription were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall 1\u2010year persistence for new users was 38.0%. Within the same period, a total of 10.3% switched from the index drug to another drug in the same group, whereas 51.7% discontinued without switching. Users of solifenacin and tolterodine were somewhat more persistent than users of darifenacin and fesoterodine. Persistence was lowest (20.9%) in the age group 18\u201339\u00a0years, increased with age and was highest in the age groups 70\u201379\u00a0years and 80\u00a0years and above (43.5 and 43.3%, respectively). In total, 31.9% filled only one prescription of the drug and, of these, only one of four women switched to another drug. The proportion who were adherent during treatment was 60.4%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The discontinuation rate for anticholinergic drugs for overactive bladder in women is high. The reasons why patients stop using them remain obscure but could be related both to a limited clinical effect and an unacceptable adverse effect burden.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aogs.12196","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T10:30:42Z","timestamp":1371119442000},"page":"1208-1215","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database"],"prefix":"10.1111","volume":"92","author":[{"given":"Siri A.","family":"Mauseth","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine Children's and Women's Health Norwegian University of Science and Technology Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology Norwegian Institute of Public Health Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Children's and Women's Health Norwegian University of Science and Technology Trondheim Norway"},{"name":"Department of Clinical Pharmacology St. Olav University Hospital Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20737"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20798"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0183-6"},{"key":"e_1_2_8_5_1","first-page":"2278","article-title":"Prevalence of overactive bladder and incontinence in Canada","volume":"11","author":"Corcos J","year":"2004","journal-title":"Can J Urol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2010.08.039"},{"key":"e_1_2_8_7_1","first-page":"1","article-title":"Is the prevalence of overactive bladder overestimated? A population based study in Finland","volume":"195","author":"Tikkinen KAO","year":"2007","journal-title":"PLoS ONE"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020124"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2011.01120.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.11185"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.23.1995"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb04692.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic rescptor antagonists for overactive bladder","volume":"100","author":"Abrams P","year":"2007","journal-title":"Br J Urol Int"},{"key":"e_1_2_8_15_1","first-page":"2061","article-title":"Newer agents for the management of overactive bladder","volume":"74","author":"Epstein BJ","year":"2006","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.3.291"},{"key":"e_1_2_8_17_1","first-page":"343","article-title":"A pharmacoeconomic model comparing two long\u2010acting treatments for overactive bladder","volume":"8","author":"Noe I","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_8_18_1","first-page":"243","article-title":"A comparison of extended\u2010release oxybutynin and tolterodine for treatment of overactive bladder in women","volume":"15","author":"Sand PK","year":"2004","journal-title":"Int Urogynocol J Pelvic Floor Dysfunct"},{"issue":"4","key":"e_1_2_8_19_1","first-page":"S118","article-title":"Challenges for managing overactive bladder and guidance for patient support","volume":"15","author":"Schabert VF","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.09.021"},{"key":"e_1_2_8_21_1","first-page":"55","article-title":"Drug utilization in a public health perspective: establishing a national prescription register in Norway","volume":"11","author":"Furu K","year":"2001","journal-title":"Nor J Epidemiol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.65269.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.4.635"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00041.x"},{"issue":"4","key":"e_1_2_8_25_1","first-page":"S108","article-title":"Pharmacotherapy adherence and costs versus versus nonpharmacologic management in overactive bladder","volume":"15","author":"Pelletier EM","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1230"},{"issue":"4","key":"e_1_2_8_27_1","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya FT","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.5.470.35064"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.1940"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.30516.x"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faogs.12196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aogs.12196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:52:49Z","timestamp":1696531969000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/aogs.12196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,11]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/aogs.12196"],"URL":"https:\/\/doi.org\/10.1111\/aogs.12196","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,11]]},"assertion":[{"value":"2012-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}